Michael M. Morrissey
Net Worth
Last updated:
What is Michael M. Morrissey net worth?
The estimated net worth of Dr. Michael M. Morrissey is at least $81,726,480 as of 1 Oct 2024. He owns shares worth $3,246,647 as insider, has earned $26,779,833 from insider trading and has received compensation worth at least $51,700,000 in Exelixis, Inc..
What is the salary of Michael M. Morrissey?
Dr. Michael M. Morrissey salary is $2,350,000 per year as Chief Executive Officer, Pres & Director in Exelixis, Inc..
How old is Michael M. Morrissey?
Dr. Michael M. Morrissey is 64 years old, born in 1961.
What stocks does Michael M. Morrissey currently own?
As insider, Dr. Michael M. Morrissey owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Exelixis, Inc. (EXEL) | Chief Executive Officer, Pres & Director | 86,485 | $37.54 | $3,246,647 |
What does Exelixis, Inc. do?
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Michael M. Morrissey insider trading
Exelixis, Inc.
Dr. Michael M. Morrissey has made 61 insider trades between 2003-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 480,000 units of EXEL stock on 1 Oct 2024. As of 1 Oct 2024 he still owns at least 86,485 units of EXEL stock.